{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T13:52:01Z","timestamp":1781531521104,"version":"3.54.5"},"reference-count":57,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T00:00:00Z","timestamp":1724371200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Studying a patient with Pompe disease (PD) is like opening Pandora\u2019s box. The specialist is faced with numerous clinical features similar to those of several diseases, and very often the symptoms are well hidden and none is associated with this rare disease. In recent years, scientific interest in this disease has been growing more and more, but still no symptom is recognized as key to a correct diagnosis of it, nor is there any specific disease marker to date. New diagnostic\/therapeutic proposals on disease allow for the diffusion of knowledge of this pathology for timely diagnosis of the patient. Due to unawareness and difficulty in diagnosis, many adults with PD are diagnosed with great delay. In this article, we report and discuss current knowledge of PD and provide new data from work conducted on a cohort of 2934 Italian subjects recruited in recent years. A genetic analysis of the GAA gene was performed on patients with significant clinical signs and pathological enzyme activity to define the genetic profile of subjects. This identified 39 symptomatic PD subjects with low acid alpha-glucosidase enzyme activity and the presence of two causative mutations in GAA gene regions. Furthermore, 22 subjects with genetic variants of uncertain significance (GVUS) were identified.<\/jats:p>","DOI":"10.3390\/ijms25179139","type":"journal-article","created":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T05:16:24Z","timestamp":1724649384000},"page":"9139","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Mutation Spectrum of GAA Gene in Pompe Disease: Current Knowledge and Results of an Italian Study"],"prefix":"10.3390","volume":"25","author":[{"given":"Marta","family":"Moschetti","sequence":"first","affiliation":[{"name":"Institute for Biomedical Research and Innovation (IRIB), National Research Council (CNR), 90146 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2287-3676","authenticated-orcid":false,"given":"Alessia","family":"Lo Curto","sequence":"additional","affiliation":[{"name":"Institute for Biomedical Research and Innovation (IRIB), National Research Council (CNR), 90146 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Giacomarra","sequence":"additional","affiliation":[{"name":"Institute for Biomedical Research and Innovation (IRIB), National Research Council (CNR), 90146 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Francofonte","sequence":"additional","affiliation":[{"name":"Institute for Biomedical Research and Innovation (IRIB), National Research Council (CNR), 90146 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmela","family":"Zizzo","sequence":"additional","affiliation":[{"name":"Institute for Biomedical Research and Innovation (IRIB), National Research Council (CNR), 90146 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Messina","sequence":"additional","affiliation":[{"name":"Institute for Biomedical Research and Innovation (IRIB), National Research Council (CNR), 90146 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Duro","sequence":"additional","affiliation":[{"name":"Institute for Biomedical Research and Innovation (IRIB), National Research Council (CNR), 90146 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2470-7030","authenticated-orcid":false,"given":"Paolo","family":"Colomba","sequence":"additional","affiliation":[{"name":"Institute for Biomedical Research and Innovation (IRIB), National Research Council (CNR), 90146 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,8,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2174\/1566524024605789","article-title":"Acid alpha-glucosidase deficiency (glycogenosis type II, Pompe disease)","volume":"2","author":"Raben","year":"2002","journal-title":"Curr. Mol. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1750-1172-7-35","article-title":"A cross-sectional single-centre study on the spectrum of Pompe disease, German patients: Molecular analysis of the GAA gene, manifestation and genotype-phenotype correlations","volume":"7","author":"Herzog","year":"2012","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1542\/peds.112.2.332","article-title":"The natural course of infantile Pompe\u2019s disease: 20 original cases compared with 133 cases from the literature","volume":"112","author":"Hop","year":"2003","journal-title":"Pediatrics"},{"key":"ref_4","first-page":"85","article-title":"Frequency of mutations for glycogen storage disease type II in different populations: The delta525T and deltaexon 18 mutations are not generally \"common\" in white populations","volume":"36","author":"Hirschhorn","year":"1999","journal-title":"J. Med. Genet."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13023-014-0102-z","article-title":"Genotype-phenotype correlation in Pompe disease, a step forward","volume":"9","author":"Saeidi","year":"2014","journal-title":"Orphanet J. Rare. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e1116","DOI":"10.1542\/peds.2008-3667","article-title":"Pompe disease in infants: Improving the prognosis by newborn screening and early treatment","volume":"124","author":"Chien","year":"2009","journal-title":"Pediatrics"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.cca.2013.10.013","article-title":"Development of a feasible assay for the detection of GAA mutations in patients with Pompe disease","volume":"429","author":"Er","year":"2014","journal-title":"Clin. Chim. Acta"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0140-6736(11)61266-X","article-title":"Neonatal screening for lysosomal storage disorders: Feasibility and incidence from a nationwide study in Austria","volume":"379","author":"Mechtler","year":"2012","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1002\/humu.20374","article-title":"Mutation profile of the GAA gene in 40 Italian patients with late onset glycogen storage disease type II","volume":"27","author":"Montalvo","year":"2006","journal-title":"Hum. Mutat."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/(SICI)1096-8628(19980827)79:1<69::AID-AJMG16>3.0.CO;2-K","article-title":"Carrier frequency for glycogen storage disease type II in New York and estimates of affected individuals born with the disease","volume":"79","author":"Martiniuk","year":"1998","journal-title":"Am. J. Med. Genet."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Tang, H., Feuchtbaum, L., Sciortino, S., Matteson, J., Mathur, D., Bishop, T., and Olney, R.S. (2020). The First Year Experience of Newborn Screening for Pompe Disease in California. Int. J. Neonatal. Screen., 6.","DOI":"10.3390\/ijns6010009"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Sawada, T., Kido, J., and Nakamura, K. (2020). Newborn Screening for Pompe Disease. Int. J. Neonatal. Screen, 6.","DOI":"10.3390\/ijns6020031"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ymgme.2017.09.008","article-title":"Insight into the phenotype of infants with Pompe disease identified by newborn screening with the common c.-32-13T>G \"late-onset\" GAA variant","volume":"122","author":"Rairikar","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/01.gim.0000218152.87434.f3","article-title":"Pompe disease diagnosis and management guideline","volume":"8","author":"Kishnani","year":"2006","journal-title":"Genet. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1067\/mpd.2000.107112","article-title":"Identification of two subtypes of infantile acid maltase deficiency","volume":"137","author":"Slonim","year":"2000","journal-title":"J. Pediatr."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s13353-018-0444-7","article-title":"Splicing mutations in human genetic disorders: Examples, detection, and confirmation","volume":"59","author":"Anna","year":"2018","journal-title":"J. Appl. Genet."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"15856","DOI":"10.18632\/aging.103794","article-title":"Pompe disease: Pathogenesis, molecular genetics and diagnosis","volume":"12","author":"Taverna","year":"2020","journal-title":"Aging"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.molmed.2021.04.005","article-title":"Therapeutic Modulation of RNA Splicing in Malignant and Non-Malignant Disease","volume":"27","year":"2021","journal-title":"Trends Mol. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"100997","DOI":"10.1016\/j.ymgmr.2023.100997","article-title":"Variants associated with reduced enzymatic activity but lack of Pompe-related symptoms, incidentally identified by exome sequencing","volume":"36","author":"Malekkou","year":"2023","journal-title":"Mol. Genet. Metab. Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"143","DOI":"10.5603\/PJNNS.a2022.0075","article-title":"Multisystem presentation of Late Onset Pompe Disease: What every consulting neurologist should know","volume":"57","year":"2023","journal-title":"Neurol. Neurochir. Pol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1086\/522236","article-title":"Enhanced response to enzyme replacement therapy in Pompe disease after the induction of immune tolerance","volume":"81","author":"Sun","year":"2007","journal-title":"Am. J. Hum. Genet."},{"key":"ref_22","first-page":"768-e31","article-title":"European consensus for starting and stopping enzyme replacement therapy in adult patients with Pompe disease: A 10-year experience","volume":"24","author":"Kruijshaar","year":"2017","journal-title":"Eur. J. Neurol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"100475","DOI":"10.1016\/j.ymgmr.2019.100475","article-title":"Characterization of immune response in Cross-Reactive Immunological Material (CRIM)-positive infantile Pompe disease patients treated with enzyme replacement therapy","volume":"20","author":"Desai","year":"2019","journal-title":"Mol. Genet. Metab. Rep."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/ajmg.c.31319","article-title":"Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: Lessons learned from 10 years of clinical laboratory testing experience","volume":"160","author":"Bali","year":"2012","journal-title":"Am. J. Med. Genet. Part C Semin. Med. Genet."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"100893","DOI":"10.1016\/j.ymgmr.2022.100893","article-title":"A favorable outcome in an infantile-onset Pompe patient with cross reactive immunological material (CRIM) negative disease with high dose enzyme replacement therapy and adjusted immunomodulation","volume":"32","author":"Curelaru","year":"2022","journal-title":"Mol. Genet. Metab. Rep."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1038\/labinvest.3700484","article-title":"Characterization of pre- and post-treatment pathology after enzyme replacement therapy for Pompe disease","volume":"86","author":"Thurberg","year":"2006","journal-title":"Lab. Invest."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.cccn.2004.04.009","article-title":"Glycogen storage disease type II: Enzymatic screening in dried blood spots on filter paper","volume":"347","author":"Chamoles","year":"2004","journal-title":"Clin. Chim. Acta"},{"key":"ref_28","first-page":"114","article-title":"New therapeutic approaches for Pompe disease: Enzyme replacement therapy and beyond","volume":"12","author":"Kishnani","year":"2014","journal-title":"Pediatr. Endocrinol. Rev."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1093\/hmg\/3.7.1081","article-title":"A de novo 13 nt deletion, a newly identified C647W missense mutation and a deletion of exon 18 in infantile onset glycogen storage disease type II (GSDII)","volume":"3","author":"Huie","year":"1994","journal-title":"Hum. Mol. Genet."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"350","DOI":"10.4103\/aian.aian_855_21","article-title":"Genetic Testing in Neurology: What Every Neurologist Must Know","volume":"25","author":"Salunkhe","year":"2022","journal-title":"Ann. Indian Acad. Neurol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Meena, N.K., and Raben, N. (2020). Pompe Disease: New Developments in an Old Lysosomal Storage Disorder. Biomolecules, 10.","DOI":"10.3390\/biom10091339"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1089\/rej.2006.9.237","article-title":"Emerging strategies for the treatment of hereditary metabolic storage disorders","volume":"9","author":"Brady","year":"2006","journal-title":"Rejuvenation Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.ymthe.2018.11.018","article-title":"mRNA-Based Protein Replacement Therapy for the Heart","volume":"27","author":"Magadum","year":"2019","journal-title":"Mol. Ther."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Coutinho, M.F., Santos, J.I., Matos, L., and Alves, S. (2016). Genetic Substrate Reduction Therapy: A Promising Approach for Lysosomal Storage Disorders. Diseases, 4.","DOI":"10.3390\/diseases4040033"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s10545-008-0873-2","article-title":"Potential efficacy of enzyme replacement and substrate reduction therapy in three siblings with Gaucher disease type III","volume":"31","author":"Bour","year":"2008","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Coutinho, M.F., Santos, J.I., and Alves, S. (2016). Less Is More: Substrate Reduction Therapy for Lysosomal Storage Disorders. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17071065"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1146\/annurev-genom-090711-163739","article-title":"Enzyme replacement therapy for lysosomal diseases: Lessons from 20 years of experience and remaining challenges","volume":"13","author":"Desnick","year":"2012","journal-title":"Annu. Rev. Genomics Hum. Genet."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1542\/peds.2006-2156","article-title":"Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: Results of a multinational study of recombinant human alpha-L-iduronidase (laronidase)","volume":"120","author":"Wraith","year":"2007","journal-title":"Pediatrics"},{"key":"ref_39","first-page":"CD011539","article-title":"Enzyme replacement therapy for infantile-onset Pompe disease","volume":"11","author":"Chen","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1750-1172-8-49","article-title":"Impact of enzyme replacement therapy on survival in adults with Pompe disease: Results from a prospective international observational study","volume":"8","author":"Kruijshaar","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/8904_2013_250","article-title":"Successful Desensitisation in a Patient with CRIM-Positive Infantile-Onset Pompe Disease","volume":"12","author":"Baruteau","year":"2014","journal-title":"JIMD Rep."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/gim.2011.4","article-title":"Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease","volume":"14","author":"Messinger","year":"2012","journal-title":"Genet. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"719","DOI":"10.4161\/auto.19469","article-title":"Autophagy in lysosomal storage disorders","volume":"8","author":"Lieberman","year":"2012","journal-title":"Autophagy"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"290","DOI":"10.21037\/atm.2019.05.56","article-title":"Pompe disease gene therapy: Neural manifestations require consideration of CNS directed therapy","volume":"7","author":"Byrne","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s11940-022-00736-1","article-title":"Pompe Disease: A Clinical, Diagnostic, and Therapeutic Overview","volume":"24","author":"Stevens","year":"2022","journal-title":"Curr. Treat. Options Neurol."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Desai, A.K., Baloh, C.H., Sleasman, J.W., Rosenberg, A.S., and Kishnani, P.S. (2020). Benefits of Prophylactic Short-Course Immune Tolerance Induction in Patients With Infantile Pompe Disease: Demonstration of Long-Term Safety and Efficacy in an Expanded Cohort. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.01727"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Banugaria, S.G., Prater, S.N., Patel, T.T., Dearmey, S.M., Milleson, C., Sheets, K.B., Bali, D.S., Rehder, C.W., Raiman, J.A., and Wang, R.A. (2013). Algorithm for the early diagnosis and treatment of patients with cross reactive immunologic material-negative classic infantile pompe disease: A step towards improving the efficacy of ERT. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0067052"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e125358","DOI":"10.1172\/jci.insight.125358","article-title":"Improved efficacy of a next-generation ERT in murine Pompe disease","volume":"4","author":"Xu","year":"2019","journal-title":"JCI Insight"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"284","DOI":"10.21037\/atm.2019.07.24","article-title":"Multisystem late onset Pompe disease (LOPD): An update on clinical aspects","volume":"7","author":"Toscano","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1152\/japplphysiol.00154.2020","article-title":"Polymorphism in exercise genes and respiratory function in late-onset Pompe disease","volume":"131","author":"Ravaglia","year":"2021","journal-title":"J. Appl. Physiol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ymgme.2013.03.002","article-title":"Screening for later-onset Pompe\u2019s disease in patients with paucisymptomatic hyperCKemia","volume":"109","author":"Spada","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.1002\/jcb.27624","article-title":"A computational method to characterize the missense mutations in the catalytic domain of GAA protein causing Pompe disease","volume":"120","author":"Tasneem","year":"2019","journal-title":"J. Cell Biochem."},{"key":"ref_53","first-page":"635","article-title":"Identification of a missense mutation in one allele of a patient with Pompe disease, and use of endonuclease digestion of PCR-amplified RNA to demonstrate lack of mRNA expression from the second allele","volume":"49","author":"Zhong","year":"1991","journal-title":"Am. J. Hum. Genet."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"278","DOI":"10.21037\/atm.2019.04.13","article-title":"Molecular genetics of Pompe disease: A comprehensive overview","volume":"7","author":"Peruzzo","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00415-017-8686-6","article-title":"Pompe disease in Austria: Clinical, genetic and epidemiological aspects","volume":"265","author":"Huemer","year":"2018","journal-title":"J. Neurol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/ped.12873","article-title":"Combination of two different homozygote mutations in Pompe disease","volume":"58","author":"Arslan","year":"2016","journal-title":"Pediatr. Int."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.gene.2015.02.023","article-title":"Novel GAA mutations in patients with Pompe disease","volume":"561","author":"Kyosen","year":"2015","journal-title":"Gene"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/17\/9139\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:41:58Z","timestamp":1760110918000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/17\/9139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,23]]},"references-count":57,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["ijms25179139"],"URL":"https:\/\/doi.org\/10.3390\/ijms25179139","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,23]]}}}